Your browser doesn't support javascript.
loading
Association between CCL5, CCL11, and CCL17 polymorphisms and atopic dermatitis risk: A systematic review and meta-analysis.
Zou, Chenghui; Zhang, Wen; Li, Mao; He, Dan; Han, Yujie; Liu, Min; Lu, Mao.
Afiliação
  • Zou C; School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, China.
  • Zhang W; School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, China.
  • Li M; Department of Dermatovenereology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
  • He D; School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, China.
  • Han Y; School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, China.
  • Liu M; Department of Dermatovenereology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
  • Lu M; Department of Dermatovenereology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
Medicine (Baltimore) ; 103(8): e36897, 2024 Feb 23.
Article em En | MEDLINE | ID: mdl-38394497
ABSTRACT

BACKGROUND:

Atopic dermatitis (AD) is a common and recurrent inflammatory disease with strong genetic susceptibility. The abnormal production of chemokines plays an important role in the occurrence and development of AD.

METHODS:

A comprehensive online literature search was performed in databases of China National Knowledge Infrastructure, Wanfang, VIP China Science and Technology Journal Database, China Biomedical Literature Database, PubMed, Embase and Cochrane Library to retrieve relevant articles published from January 2000 to October 2022. The odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate this relationship.

RESULTS:

A total of 7 studies were finally screened out, including 1316 AD patients and 1099 controls. There were 3 studies for CC chemokine ligand 5 (CCL5) polymorphisms, 2 for CCL11 polymorphisms, and 2 for CCL17 polymorphisms, respectively. The meta-analysis revealed a significant association between the CCL5 - 403G/A polymorphism and AD under the allelic model (A vs G OR = 1.25, 95% CI = 1.02-1.52, P = .03), heterozygous model (AG vs GG OR = 1.40, 95% CI = 1.08-1.80, P = .01) and dominant model (AA + AG vs GG OR = 1.38, 95% CI = 1.08-1.76, P = .01) in a fixed-effect model. The allelic model (G vs C OR = 1.46, 95% CI = 1.07-1.98, P < .01) and dominant model (GG + GC vs CC OR = 1.74, 95% CI = 1.23-2.47, P < .001) of the CCL5 - 28C/G polymorphism were also associated with an increased risk of AD. However, this significant association was not found in other alleles and genotypes (P > .05).

CONCLUSION:

Our results show that the A allele, AG and AA + AG genotypes of the CCL5 - 403G/A polymorphism, the G allele and GG + GC genotype of the CCL5 - 28C/G polymorphism are risk factors for AD. Future studies with large population are still needed to further explore those correlations.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimiocina CCL5 / Dermatite Atópica / Quimiocina CCL11 / Quimiocina CCL17 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimiocina CCL5 / Dermatite Atópica / Quimiocina CCL11 / Quimiocina CCL17 Idioma: En Ano de publicação: 2024 Tipo de documento: Article